The last meeting...and the lasting one.
 
National Cabinet examines COVID-19 vaccine rollout strategy
 
The Crisis Buster – Four-Step Plan to tackle Covid and ensure a bright future
 
Kuwait participates in Arab-German Health Forum
 
Lebanese presidential office explains decision to expel journalist from palace
 
France needs to avoid walking in America’s steps
 
First day at Grand Serail Mikati says people's needs top priority
 
Strong Lebanon: Affirmed that giving confidence to the government was linked to the contents of its ministerial statement...
 
Kuwait defeats Uzbekistan in Asian volleyball championship
 
Gemayel meets in Egypt with Petroleum & Mineral Resources Minister
 
Pope Warns Of 'Threat Of Antisemitism' In Europe
 
France issues special postage stamp marking French-Kuwaiti friendship
 
Earlier diagnosis of cancers leads to dramatically increased survival rates.

Britain begins world's largest trial of blood test for 50 types of cancer




Britain begins world's largest trial of blood test for 50 types of cancer

13 Sep 2021

London - Britain's state-run National Health Service will on Monday begin the world's biggest trial of Grail Inc's flagship Galleri blood test that can be used to detect more than 50 types of cancer before symptoms appear.

The Galleri test looks at the DNA in a patient's blood to determine if any come from cancer cells. Earlier diagnosis of cancers leads to dramatically increased survival rates.

The NHS said it wanted to recruit 140,000 volunteers in England to see how well the test worked as part of a randomised control trial. Half of the participants will have their blood sample screened with the Galleri test right away.

"We need to study the Galleri test carefully to find out whether it can significantly reduce the number of cancers diagnosed at a late stage," said Peter Sasieni, professor of cancer prevention at King's College London.

"The test could be a game changer for early cancer detection and we are excited to be leading this important research."

Lung cancer is by far the most common cause of cancer death in the United Kingdom, accounting for around a fifth of all cancer deaths. Lung, bowel, prostate and breast cancers account for 45% of the United Kingdom's cancer deaths, the NHS said.

US life sciences company Illumina Inc said last month it had completed its $7.1 billion acquisition of Grail. Illumina said it will operate Grail separately from its existing business. --




 














Copyright 2007 mideast-times.com